Intra-Cellular Therapies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intra-Cellular Therapies, Inc.
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.
New Products Shake Up Overlooked Bipolar Disorder Market
The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.
Fears For Ukraine’s Access To Medicines And Trials As Russian Invasion Continues
The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues, while a US biopharma group is calling for industries to boycott all non-food and medical trade with Russia.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.